PRESENT STATUS OF ANTICOAGULANT THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION; THE USE AND MISUSE OF ANTICOAGULANTS; AN EVALUATION OF NEW ANTICOAGULANTS, THEIR INDICATIONS AND DOSAGE

The use of anticoagulant therapy in the treatment of myocardial infarction is rapidly becoming accepted in medical centers and leading hospitals throughout the civilized world.

Abstract

Article1 November 1955PRESENT STATUS OF ANTICOAGULANT THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION; THE USE AND MISUSE OF ANTICOAGULANTS; AN EVALUATION OF NEW ANTICOAGULANTS, THEIR INDICATIONS AND DOSAGEIRVING S. WRIGHT, M.D., F.A.C.P.IRVING S. WRIGHT, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-5-942 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe use of anticoagulant therapy in the treatment of myocardial infarction is rapidly becoming accepted in medical centers and leading hospitals throughout the civilized world.1It is also being used well in many small communities where there exists the fortunate combination of a well trained, conscientious physician and a good laboratory capable of performing accurate prothrombin time tests.2While the report of the Committee on Anticoagulants of The American Heart Association constitutes the most comprehensive and detailed evaluation of this therapy, reports from more than 40 institutions confirming this study have appeared from the United States and foreign countries. In...Bibliography1. Thrombosis and embolism. I. International Conference, Basel, 1954, edited by T. Koller, and W. R. Merz, 1955, Benno Schwabe & Co., Basel. Google Scholar2. Stephens CA: Anticoagulant therapy in private practice, Circulation 9: 682-686 (May) 1954. CrossrefMedlineGoogle Scholar3. WrightMarpleBeck ISCD: Myocardial infarction—its clinical manifestations and treatment with anticoagulants, 1954, Grune & Stratton, New York. Google Scholar4. Rytand DA: Anticoagulants in coronary thrombosis with myocardial infarction, Arch. Int. Med. 88: 207-210 (Aug.) 1951. CrossrefGoogle Scholar5. DoscherPoindexter NCA: Myocardial infarction without anticoagulant therapy—deaths, emboli, and an analysis of factors influencing mortality, Am. J. Med. 8: 623-633 (May) 1950. CrossrefMedlineGoogle Scholar6. Evans W: Anticoagulant therapy in coronary occlusion, Proc. Roy. Soc. Med. 47: 318, 1954. CrossrefMedlineGoogle Scholar7. FeldmanSchaeferGoldsteinForman LGLSEIM: Bishydroxycoumarin (Dicumarol) therapy in myocardial infarction, Arch. Int. Med. 94: 433-437 (Sept.) 1954. CrossrefGoogle Scholar8. BresnickSelverstoneRapoportCheskeyHultgrenSise ELABKHNHS: Experiences with Dicumarol in acute myocardial infarction, New England J. Med. 243: 806-810, 1950. CrossrefMedlineGoogle Scholar9. FurmanBallGaleBillingsMeneeley RHOTRGFTGR: An evaluation of anticoagulant therapy in myocardial infarction based on prognostic categories, Am. J. Med. 14: 681-688 (June) 1953. CrossrefMedlineGoogle Scholar10. RussekZohman HIBL: Selective vs. routine use of anticoagulants in acute myocardial infarction, J. A. M. A. 156: 1130, 1954. CrossrefMedlineGoogle Scholar11. Schnur S: The current dispute concerning anticoagulants in acute myocardial infarction, J. A. M. A. 156: 1127, 1954. CrossrefMedlineGoogle Scholar12. BaerHeineKrasnoff SWISO: The mortality of acute myocardial infarction in practice, Am. J. M. Sc. 222: 500, 1951. CrossrefMedlineGoogle Scholar13. Levy R: Statement made before Annual Meeting, American Heart Association, 1953. Google Scholar14. Nichol S: Statement made before Annual Meeting, American Heart Association, 1953. Google Scholar15. HalpernLembergBelleEichert MMLMH: The selective use of anticoagulants in acute myocardial infarction based on initial prognosis, Ann. Int. Med. 41: 942-951 (Nov.) 1954. LinkGoogle Scholar16. WinerZollBlumgart BMPMH: Personal communication, March 15, 1954. Google Scholar17. de FranciscoWright AIS: Thromboembolic complications following so-called "good risk cases" of myocardial infarction, in preparation. Google Scholar18. NicholFassett ESDW: An attempt to forestall acute coronary thrombosis: preliminary note on the continuous use of Dicumarol, South. M. J. 40: 631 (Aug.) 1947. CrossrefMedlineGoogle Scholar19. Lund E: Long term Dicumarol therapy in thromboembolic conditions, especially coronary thrombosis, Acta med. Scandinav. 146: 252, 1953. CrossrefMedlineGoogle Scholar20. KeyesDrakeJamesSmith JWEHTNFJ: Survival rates after myocardial infarctions with and without long term anticoagulant therapy, Am. J. M. Sc. 226: 607, 1953. CrossrefMedlineGoogle Scholar21. SuzmanRuskinGoldberg MMHDB: An evaluation of the effect of continuous long term anticoagulant therapy on the prognosis of myocardial infarction, Circulation, to be published. Google Scholar22. NicholBorg ESJF: Long term Dicumarol therapy to prevent recurrent coronary artery thrombosis, Circulation 1: 1097, 1950. CrossrefMedlineGoogle Scholar23. Owren P: Long term Dicumarol therapy in cardiovascular diseases, Acta med. Scandinav. Supp. 287, 147: 46, 1953. Google Scholar24. FoleyMcDevittSymonsWright WTECIS: Further experiences with long term anticoagulant therapy, Arch. Int. Med. 95: 497 (Apr.) 1955. CrossrefGoogle Scholar25. WrightFoley ISWT: Use of anticoagulants in the treatment of heart disease with special reference to coronary thrombosis, rheumatic heart disease with thromboembolic complications, Am. J. Med. 3: 718 (Dec.) 1947. CrossrefMedlineGoogle Scholar26. TullochWright JIS: Long term anticoagulant therapy, further experiences, Circulation 9: 823 (June) 1954. CrossrefMedlineGoogle Scholar27. FoleyWright WTIS: The treatment of cerebral thrombosis and embolism with anticoagulant drugs—preliminary observations, M. Clin. North America 34: 909 (May) 1950. CrossrefMedlineGoogle Scholar28. WrightMcDevitt ISE: Cerebral vascular diseases, their significance, diagnosis and present treatment, including the selective use of anticoagulant substances, Ann. Int. Med. 41: 682 (Oct.) 1954. LinkGoogle Scholar29. Wright IS: The pathogenesis and treatment of thrombosis, Circulation 5: 161, 1952. CrossrefMedlineGoogle Scholar30. Wright IS: The use of anticoagulants in the treatment of diseases of the heart and blood vessels, Ann. Int. Med. 30: 80 (Jan.) 1949. LinkGoogle Scholar31. BurkeWright GEIS: Tromexan—experimental and clinical properties, Circulation 3: 164, 1951. CrossrefMedlineGoogle Scholar32. HunterTudhope RBGR: Mode of action of Tromexan, Lancet 1: 821 (Apr. 25) 1953. CrossrefMedlineGoogle Scholar33. BattleCappsOrthMeyer WDRTOSOO: The effects of 4-hydroxycoumarin anticoagulant No. 63 upon the prothrombin time in dogs and human beings, J. Lab. and Clin. Med. 35: 8, 1950. MedlineGoogle Scholar34. BourgainToddHerzigWright RMLIS: Marcumar—(3-(1′-phenylpropyl)-4-hydroxycoumarin), a new anticoagulant, Circulation 10: 680-684 (Nov.) 1954. CrossrefMedlineGoogle Scholar35. ClatanoffTriggsMeyer DVPOOO: Clinical experience with coumarin anticoagulants Warfarin and Warfarin Sodium, Arch. Int. Med. 94: 213 (Aug.) 1954. CrossrefGoogle Scholar36. Shapiro S: Hypoprothrombinemia-inducing activity of Warfarin Sodium (Coumadin Sodium), J. Kansas M. Soc. 55: 687-691 (Dec.) 1954. MedlineGoogle Scholar37. BlausteinCroceAlberianRichey AUJJMN: Preliminary report on the clinical use of a new anticoagulant, phenylindanedione, Circulation 1: 1195, 1950. CrossrefMedlineGoogle Scholar38. FieldGoldfarbWareGriffith JBMSAGGC: Dipaxin-2-Diphenylacetyl-1,3-Indanedione; clinical evaluation of a new anticoagulant, Circulation 11: 576-583 (Apr.) 1955. CrossrefMedlineGoogle Scholar39. SorensonWright CWIS: A synthetic anticoagulant: a polysulfuric acid ester of polyanhydromannuronic acid (Paritol), Circulation 2: 658, 1950. CrossrefMedlineGoogle Scholar40. HirschboeckMadison JSFW: A comparison of the anticoagulant properties of a polyhexuronic acid ester with sodium heparin, J. Lab. and Clin. Med. 36: 836, 1950. MedlineGoogle Scholar41. SheppardBourgainSymonsWright ERCIS: The effect of phosphorylated and sulfonated hesperidin on blood coagulation, Arch. Biochem. and Biophys. 50: 224 (May) 1954. CrossrefMedlineGoogle Scholar42. SheppardImperanteWright EJIS: The effect of phosphorylated hesperidin on the polymerization of fibrinogen as studied by light-scattering, J. Biol. Chem. 212: 837 (Feb.) 1955. CrossrefMedlineGoogle Scholar43. BourgainSymonsToddWright RCMIS: The action of phosphorylated hesperidin on blood coagulation, J. Pharmacol. and Exper. Therap. 112: 393 (Dec.) 1954. MedlineGoogle Scholar44. InnerfieldSchwartzAngrist IAA: Intravenous trypsin—its anticoagulant, fibrinolytic thrombolytic effects, J. Clin. Investigation 31: 1049, 1952. CrossrefMedlineGoogle Scholar45. Tagnon JJ: Effect of intravenous injection of trypsin on the blood coagulation time in hemophilia, Proc. Soc. Exper. Biol. and Med. 57: 45, 1944. CrossrefGoogle Scholar46. TaylorOvermanWright ARSIS: Studies with crystalline trypsin. Results and hazards of intravenous administration and its postulated role in blood coagulation, J. A. M. A. 155: 347-351, 1954. CrossrefMedlineGoogle Scholar47. TaylorWright AIS: Intravenous trypsin, Circulation 10: 331-337 (Sept.) 1954. CrossrefMedlineGoogle Scholar48. LiebermanTaylorWright JSAIS: The effect of intravenous trypsin administration on the electrocardiogram of the rabbit, Circulation 10: 338-342 (Sept.) 1954. CrossrefMedlineGoogle Scholar49. FisherWilensky MMND: Parenteral trypsin in peripheral vascular and thromboembolic diseases, New York State J. Med. 54: 659-662 (Mar. 1) 1954. MedlineGoogle Scholar50. ClifftonCannamela EED: Fibrinolytic and proteolytic activity of a human "plasminogen," prepared from fraction III of human plasma, J. Appl. Physiol. 6: 42-50 (July) 1953. CrossrefMedlineGoogle Scholar51. ClifftonCannamelaGrossi EEDC: In vivo studies of human plasmin. Intravenous injection in dogs and rabbits, J. Appl. Physiol. 6: 143-150 (Sept.) 1953. CrossrefMedlineGoogle Scholar52. ClifftonGrossiCannamela EECD: Lysis of thrombi produced by sodium morrhuate in the femoral vein of dogs by human plasmin (fibrinolysin), Ann. Surg. 139: 52-62 (Jan.) 1954. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*From the Symposium on Acute Myocardial Infarction, presented at the Thirty-sixth Annual Session of The American College of Physicians, Philadelphia, Pennsylvania, April 26, 1955.From the Cornell University Medical College, New York, N. Y.Aided by grants from the Kress, Lasker, Hampil and Hyde Foundations. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGeneral AspectsClinical Applications of AspirinWhy we should not skip aspirin in cardiovascular preventionPsychological Aspects of Coronary Heart DiseaseThe Physician's Responsibility in the Age of Therapeutic PlentyAnticoagulant Treatment in Acute Coronary Occlusion with "So-Called" Ischemic PatternAnticoagulation Therapy TodayORAL AND INTRAVENOUS ESTROGENS IN THE TREATMENT AND PREVENTION OF BLEEDING ASSOCIATED WITH LONG-TERM ANTICOAGULANT THERAPYHeparin Administration after Acute Myocardial InfarctionDie Coronarerkrankungen. Coronarinsuffizienz, Angina pectoris und HerzinfarktDicumarol, Coumadin, Marcumar and TromexanPhenprocoumon (marcumar)∗Clinical Evaluation of a New Oral Anticoagulant "Sintrom"Intramuscular Injection of Trypsin: Its Value as a Thrombolytic and Anti-Inflammatory AgentAnticoagulant therapy in coronary artery diseaseThe Treatment of Cerebrovascular AccidentTHE EFFECTIVENESS OF AN ORAL VITAMIN K1 IN CONTROLLING EXCESSIVE HYPOPROTHROMBINEMIA DURING ANTICOAGULANT THERAPY*STUART W. COSGRIFF, M.D.The present status of anticoagulants 1 November 1955Volume 43, Issue 5Page: 942-954KeywordsAcute myocardial infarctionAnticoagulant therapyAnticoagulantsHeartHemorrhageLongitudinal studiesMyocardial infarctionPatientsProthrombin timeResearch laboratories ePublished: 1 December 2008 Issue Published: 1 November 1955 PDF downloadLoading ...